Pfizer Limited
NSE: PFIZER BSE: PFIZER
Prev Close
4164.2
Open Price
4165
Volume
21,385
Today Low / High
4125 / 4199
52 WK Low / High
3701 / 6451.15
Range
3,982 - 4,401
Prev Close
4165.35
Open Price
4165.4
Volume
1,468
Today Low / High
4123.5 / 4199
52 WK Low / High
3742.9 / 6452.85
Range
3,982 - 4,401
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 4191.4 (target range: 3,982 - 4,401), reflecting a change of 27.2 (0.65319%). On the BSE, it is listed at 4191.9 (target range: 3,982 - 4,401), showing a change of 26.55 (0.6374%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Pfizer Limited Graph
Pfizer Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Pfizer Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 4,191.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 4,191.90 | 4,233.82 | 3,810.44 - 4,657.20 |
| 4,275.74 | 3,420.59 - 5,130.89 | ||
| 4,317.66 | 3,022.36 - 5,612.95 | ||
| Bearish Scenario | 4,191.90 | 4,149.98 | 3,734.98 - 4,564.98 |
| 4,108.06 | 3,286.45 - 4,929.67 | ||
| 4,066.14 | 2,846.30 - 5,285.99 |
Overview of Pfizer Limited
ISIN
INE182A01018
Industry
Drug Manufacturers - General
Vol.Avg
48,036
Market Cap
191,747,043,905
Last Dividend
35
Official Website
IPO Date
2002-07-01
DCF Diff
491.43
DCF
3,686
Financial Ratios Every Investor Needs
Stock Dividend of PFIZER
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-08-21 | August 21, 24 | 35 | 35 | 2024-08-21 | 2024-09-06 | |
| 2023-08-11 | August 11, 23 | 35 | 35 | 2023-08-11 | 2023-09-16 | |
| 2022-09-19 | September 19, 22 | 30 | 30 | 2022-09-20 | 2022-09-30 | |
| 2022-08-18 | August 18, 22 | 35 | 35 | 2022-08-19 | 2022-09-23 | |
| 2021-08-11 | August 11, 21 | 5 | 5 | 2021-08-12 | 2021-09-15 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 2,192.69 Cr | 795.23 Cr | 1,397.46 Cr | 0.6373 | 0.00 Cr | 103.80 Cr | 577.06 Cr | 551.33 Cr | 120.51 | 823.78 Cr | 0.2514 |
| 2023-03-31 | 2,424.76 Cr | 873.67 Cr | 1,551.09 Cr | 0.6397 | 0.00 Cr | 264.66 Cr | 804.40 Cr | 623.93 Cr | 136.38 | 941.51 Cr | 0.2573 |
| 2022-03-31 | 2,610.55 Cr | 948.03 Cr | 1,662.52 Cr | 0.6368 | 0.00 Cr | 129.15 Cr | 778.53 Cr | 612.56 Cr | 133.89 | 897.20 Cr | 0.2346 |
| 2021-03-31 | 2,238.43 Cr | 797.74 Cr | 1,440.69 Cr | 0.6436 | 0.00 Cr | 97.29 Cr | 678.36 Cr | 497.61 Cr | 108.77 | 792.13 Cr | 0.2223 |
| 2020-03-31 | 2,151.51 Cr | 792.40 Cr | 1,359.11 Cr | 0.6317 | 0.00 Cr | 86.71 Cr | 619.47 Cr | 509.13 Cr | 111.28 | 755.36 Cr | 0.2366 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 112.00 Cr | 4,228.78 Cr | 633.24 Cr | 3,595.5400 Cr | 94.54 Cr | -17.46 Cr | 433.69 Cr | 151.52 Cr | 56.63 Cr | 0.00 Cr | -1,900.32 Cr | 546.5600 Cr |
| 2023-03-31 | 36.60 Cr | 4,000.73 Cr | 793.43 Cr | 3,207.3000 Cr | 134.47 Cr | 97.87 Cr | 417.70 Cr | 185.46 Cr | 3.48 Cr | 0.00 Cr | 0.00 Cr | 657.3500 Cr |
| 2022-03-31 | 62.76 Cr | 3,900.51 Cr | 1,036.10 Cr | 2,864.4100 Cr | 166.99 Cr | 104.23 Cr | 448.90 Cr | 220.07 Cr | 1.43 Cr | -10.25 Cr | 7.48 Cr | 852.8900 Cr |
| 2021-03-31 | 157.03 Cr | 3,265.90 Cr | 872.86 Cr | 2,393.0400 Cr | 105.91 Cr | -51.12 Cr | 435.05 Cr | 195.14 Cr | 202.63 Cr | 0.00 Cr | 434.48 Cr | 774.3400 Cr |
| 2020-03-31 | 1,763.79 Cr | 4,405.40 Cr | 1,009.91 Cr | 3,395.4900 Cr | 127.93 Cr | -1,635.86 Cr | 430.59 Cr | 215.28 Cr | 189.33 Cr | 0.00 Cr | 293.04 Cr | 873.3600 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 256.8400 Cr | -75.1300 Cr | -235.1400 Cr | 237.9100 Cr | 75.4000 Cr | 112.0000 Cr | -18.9300 Cr | 551.3300 Cr | 0.0000 Cr | -183.4300 Cr | -16.0000 Cr |
| 2023-03-31 | 355.6800 Cr | -36.0500 Cr | -345.7900 Cr | 290.7000 Cr | -26.1600 Cr | 36.6000 Cr | -64.9800 Cr | 824.0100 Cr | -35.2000 Cr | -297.2100 Cr | 21.8500 Cr |
| 2022-03-31 | 667.0800 Cr | -575.0200 Cr | -180.5100 Cr | 651.7700 Cr | -88.4500 Cr | 62.7600 Cr | -15.3100 Cr | 772.8900 Cr | -9.8900 Cr | -159.7400 Cr | -13.8600 Cr |
| 2021-03-31 | 427.3300 Cr | -468.8400 Cr | -1,571.0700 Cr | 409.6300 Cr | -1,612.5800 Cr | 151.2100 Cr | -17.7000 Cr | 668.7200 Cr | -49.0900 Cr | -1,519.3500 Cr | -4.4600 Cr |
| 2020-03-31 | 323.1800 Cr | 1,530.3200 Cr | -163.5200 Cr | 306.2900 Cr | 1,689.9800 Cr | 1,763.7900 Cr | -16.8900 Cr | 692.9900 Cr | 0.0000 Cr | -124.0900 Cr | -93.9300 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 537.99 Cr | 196.56 Cr | 341.43 Cr | 0.6346 | 131.19 Cr | 127.60 Cr | 27.89 | 188.75 Cr | 0.2372 |
| 2024-09-30 | 588.59 Cr | 326.47 Cr | 262.12 Cr | 0.4453 | 174.26 Cr | 158.35 Cr | 34.61 | 232.32 Cr | 0.2690 |
| 2024-06-30 | 562.86 Cr | 306.66 Cr | 256.20 Cr | 0.4552 | 162.89 Cr | 150.71 Cr | 32.94 | 177.49 Cr | 0.2678 |
| 2024-03-31 | 546.63 Cr | 278.20 Cr | 268.43 Cr | 0.4911 | 175.68 Cr | 178.86 Cr | 39.10 | 264.56 Cr | 0.3272 |
| 2023-12-31 | 539.97 Cr | 182.56 Cr | 357.41 Cr | 0.6619 | 170.85 Cr | 129.98 Cr | 28.41 | 196.35 Cr | 0.2407 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 35.34 Cr | 2,245.98 Cr | 2,281.32 Cr | 227.51 Cr | 454.82 Cr | 3,022.73 Cr | 135.27 Cr | 4,458.60 Cr | 707.73 Cr |
| 2024-06-30 | -2,046.71 Cr | 4,093.42 Cr | 2,046.71 Cr | 0.00 Cr | 0.00 Cr | 2,046.71 Cr | 0.00 Cr | 0.00 Cr | -3,595.54 Cr |
| 2024-03-31 | 2,046.71 Cr | 1,947.73 Cr | 2,046.71 Cr | 187.61 Cr | 433.69 Cr | 2,737.81 Cr | 151.35 Cr | 4,228.78 Cr | 633.24 Cr |
| 2023-12-31 | -1,892.16 Cr | 3,784.32 Cr | 1,892.16 Cr | 0.00 Cr | 0.00 Cr | 1,892.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 15.78 Cr | 1,892.60 Cr | 1,908.38 Cr | 173.51 Cr | 399.08 Cr | 2,549.43 Cr | 173.30 Cr | 4,006.20 Cr | 733.21 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 150.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 178.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 129.98 Cr | 35.10 Cr | 0.00 Cr | 0.00 Cr | 35.10 Cr | 1,927.26 Cr | 1,892.16 Cr | 0.00 Cr | 35.10 Cr |
| 2023-09-30 | 148.96 Cr | 30.86 Cr | 0.00 Cr | 0.00 Cr | 30.86 Cr | 1,892.16 Cr | 1,861.30 Cr | 0.00 Cr | 30.86 Cr |
| 2023-06-30 | 93.53 Cr | 31.10 Cr | 0.00 Cr | 0.00 Cr | 31.10 Cr | 84.70 Cr | 53.60 Cr | 0.00 Cr | 31.10 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2000-06-12 | June 12, 00 | 2:1 |
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,511.10 | ₹1,220,390,199,810.00 | ₹570,127.00 |
| Abbott India Limited | ABBOTINDIA | ₹30,915.00 | ₹656,922,171,330.00 | ₹7,917.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,815.40 | ₹476,945,765,016.00 | ₹85,191.00 |
| Gland Pharma Limited | GLAND | ₹1,464.40 | ₹241,269,301,448.00 | ₹333,283.00 |
| Pfizer Limited | PFIZER | ₹4,191.40 | ₹191,747,043,905.00 | ₹21,385.00 |
| Sanofi India Limited | SANOFI | ₹6,306.50 | ₹145,238,695,000.00 | ₹21,446.00 |
| Marksans Pharma Limited | MARKSANS | ₹214.13 | ₹97,035,955,929.00 | ₹626,692.00 |
Key Executives
Gender: male
Year Born: 1978
Gender: male
Year Born:
Gender: male
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: female
Year Born: 1970
FAQs about Pfizer Limited
The CEO is Ms. Meenakshi Nevatia.
The current price is ₹4,191.40.
The range is ₹3701-6451.15.
The market capitalization is ₹19,174.70 crores.
The dividend yield is 7.66%.
The P/E ratio is 15.61.
The company operates in the Healthcare sector.
Overview of Pfizer Limited (ISIN: INE182A01018) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹19,174.70 crores and an average daily volume of 48,036 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹35.